Merck and EyeBiotech Limited, have announced that the two companies have entered into a definitive agreement under which Merck, through one of its subsidiaries, will acquire EyeBio.

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon.

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global compounding operator as well as to allow icon to enter the UK market.

Biogen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire HI-Bio for $1.15bn upfront, alongside up to $650m in potential milestone payments.

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos for an approximate $137.5m ‒ or $20.42 per share ‒ adding to its portfolio in inflammatory and autoimmune diseases.

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, totalling an approximate $4.9bn.

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J will acquire all outstanding shares of Shockwave Medical for $335 per share, or a total value of $13.1bn.

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the EU, UK and Switzerland.

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon Therapeutics, meaning it is now a wholly owned subsidiary of Merck.

Johnson & Johnson has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger transaction with a total equity value of approximately $2bn.